BRYAN REED: Open Payments
NPI 1811626187 · GREENSBURG, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,270 in 111 payments from 12 companies in 2025. Trend: 2023 $787 · 2024 $1,894 · 2025 $2,270
Food & beverage: $2,158Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $469 |
| Teva Pharmaceuticals USA, Inc. | 16 | $321 |
| Neurocrine BioSciences, Inc. | 14 | $269 |
| Alkermes, Inc. | 12 | $246 |
| Janssen Pharmaceuticals, Inc | 8 | $209 |
| Otsuka America Pharmaceutical, Inc. | 12 | $209 |
| Lundbeck LLC | 10 | $187 |
| Supernus Pharmaceuticals, Inc. | 6 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $97 |
| Axsome Therapeutics, Inc. | 3 | $52 |
Products named: VRAYLAR, REXULTI, INGREZZA, LYBALVI, Qelbree, SPRAVATO, UZEDY, CAPLYTA.
Industry payments across PA — which companies pay providers there.
